Legacy Healthcare aims to develop novel drugs for autoimmune, inflammatory and aging-related conditions, safe enough for chronic use especially by fragile population, e.g. children, cancer patients and the elderly, who may be already on multiple medications. Our first drug, Coacillium, is currently in Phase II/III testing for the treatment of Alopecia Areata, a debilitating scalp condition with intense medical and psychological impact on all patients, especially in children, and their families. Coacillium’s safety profile is without equal. For this reason health authorities have taken the unusual step of authorizing testing in children (starting at age 2) before adult testing. We expect Coacillium to be approved by 2023, as the first drug for Pediatric Alopecia Areata.